As of 2026-03-25, the Fair Value of BridgeBio Pharma Inc (BBIO) is -18.70 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 68.53 USD, the upside of BridgeBio Pharma Inc is -127.28%.
With the market price of 68.53 USD and our fair value calculation, BridgeBio Pharma Inc (BBIO) is not a good investment. Investing in BridgeBio stocks now will result in a potential loss of 127.28%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | 5Y Avg | |
| Net income | -562.54 | -481.18 | -643.20 | -535.76 | -724.93 | -589.52 |
| YoY growth | -25.37% | 14.46% | -33.67% | 16.70% | -35.31% | -12.64% |
| Market Cap (mil) | 13,285.23 |
| P/E | |
| Forward P/E |
| EPS | -3.74 |
| Avg earnings growth rate | -12.64% |
| TTM earnings | -724.93 |